文献速递冠心病

意大利多中心调查:心肌桥的有创功能学评估现状

Real‐World Invasive Evaluation of Myocardial Bridging: A Multicenter Italian Survey of Interventional Cardiologists' Practices
RSS 订阅 · Catheterization and Cardiovascular Interventions · 2026-10-16

一项覆盖意大利28个中心的在线调查纳入93名介入心脏病医生,描述心肌桥的真实世界管理实践。结果显示,有创功能学工具虽可及且多数医生认可其价值,但在心肌桥表型评估、痉挛激发和微循环功能检测中使用率低且差异大。主要障碍为证据不确定、操作时间和经验有限,93.5%的医生愿意参与随机试验。

要点

  • 57.0%的术者在不到10%的心肌桥病例中行功能学评估,19.4%从未做过
  • 87.1%认可「全生理学」评估有助于机制识别和个体化治疗
  • 专用评估方案仅26.9%,93.5%愿意加入随机对照研究

核心结论

  • 心肌桥的有创功能学评估虽有工具可及且医生认可其价值,但实际使用率低、实践差异大
  • 缺乏循证指导,需要专门的机制研究和标准化有创评估流程

研究设计与样本

  • 对意大利28个中心的介入心脏病医生进行匿名在线调查
  • 共93名医生应答,平均年龄38.8±8.6岁,82.8%为男性

主要发现

  • 57.0%在不到10%的心肌桥病例中行功能学评估,19.4%从未进行
  • 心外膜心肌桥评估主要依赖腺苷FFR(33.3%)或iFR(31.2%),应激增强方案很少使用
  • 乙酰胆碱激发试验在常规实践中使用率为79.6%,但仅49.5%用于评估心肌桥相关痉挛
  • 心肌桥病例中冠状动脉微循环功能检测罕见,66.7%的医生在不到10%的病例中开展
  • 87.1%认可「全生理学」评估对机制识别和个体化治疗有用

关键数值与推荐

  • 压力导丝指标广泛用于心外膜冠心病,但心肌桥表型评估不常见
  • 心肌桥心外膜评估主要采用腺苷FFR(33.3%)或iFR(31.2%)
  • 专用评估方案存在率26.9%,登记系统39.8%,常规数据采集34.4%

临床怎么用

  • 对心肌桥患者可考虑结合乙酰胆碱激发试验评估痉挛,但当前使用率仅49.5%
  • 识别机制后再制定个体化治疗策略,而非直接进行介入或药物治疗
  • 建立标准化有创评估流程和登记系统有助于减少实践差异

局限性

  • 调查应答可能存在选择偏倚,未说明总发放问卷数量
  • 自报实践与实际操作之间可能存在差异
  • 仅限意大利中心,结果向其他地区推广需谨慎

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background Myocardial bridging (MB) is increasingly recognized as a potential cause of ischemia through heterogeneous mechanisms, yet real-world management remains heterogeneous. We surveyed interventional cardiologists to describe contemporary MB practice, focusing on functional assessments, perceived value, and barriers to the “full-physiology” approach, and priorities for standardization and research. Aims To characterize contemporary MB management among interventional cardiologists, focusing on physiology approaches, imaging strategies, and perceived barriers to implementation and treatment. Methods An anonymized online survey was conducted among interventional cardiologists from 28 Italian centers. Items covered MB-specific functional assessment strategies, therapies, implementation barriers, operational infrastructure, and research interest. Results Ninety-three cardiologists responded (mean age 38.8 ± 8.6 years; 82.8% male). Pressure-based indices were widely used for epicardial CAD, but phenotyping in MB was uncommon: 57.0% performed physiology in < 10% of MB cases, and 19.4% never did. Epicardial MB assessment relied mainly on adenosine-FFR (33.3%) or iFR (31.2%), whereas stress-enhanced protocols were rarely used. Although intracoronary acetylcholine testing was commonly used in general practice (79.6%), only 49.5% of respondents reported using it to assess MB-related coronary spasm, and most did so in only a small proportion of cases. CMD testing in MB was rare (< 10% in 66.7%). Despite this, most respondents (87.1%) endorsed “full-physiology” as useful for mechanism identification and personalized therapy, but cited evidence uncertainty, procedural time, and limited experience as key barriers. Operational readiness was low (dedicated protocols: 26.9%; registries: 39.8%; routine capture: 34.4%). Willingness to join a randomized trial was high (93.5%). Conclusions Despite the widespread availability of invasive functional assessment tools and operators' recognition of their relevance, their use in MB remains limited and heterogeneous, reflecting the lack of evidence-based guidance and underscoring the need for dedicated mechanistic studies and standardized invasive workflows.

来源:Catheterization and Cardiovascular Interventions,查看原文。版权归原作者所有。

引用

  1. Catheterization and Cardiovascular Interventions:Real‐World Invasive Evaluation of Myocardial Bridging: A Multicenter Italian Survey of Interventional Cardiologists' Practices

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。